Skip to main content
. 2017 Mar 11;79(4):651–660. doi: 10.1007/s00280-016-3237-x

Fig. 1.

Fig. 1

Anti-tumor activity of pembrolizumab per RECIST v1.1 by central review. a Best change from baseline in the sum of the longest target lesion diameters for each patient. b Treatment exposure and duration of response per patient. c Longitudinal changes in the sum of the longest target lesion diameters for each patient